We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.78%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$20.2M
Cap. Flow
+$2M
Cap. Flow %
1.36%
Top 10 Hldgs %
70.43%
Holding
67
New
5
Increased
11
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$1.19M
2
PRTA icon
Prothena Corp
PRTA
+$621K
3
CYTK icon
Cytokinetics
CYTK
+$442K
4
GOSS icon
Gossamer Bio
GOSS
+$368K
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$239K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.05M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$826K
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$373K
4
HOOK
HOOKIPA Pharma
HOOK
+$183K
5
CCXI
ChemoCentryx, Inc.
CCXI
+$77.9K

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Energy 2.11%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$47.1M 32.05%
796,106
– –
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$13.1M 8.91%
225,239
+1,953
+0.9% +$127K
BDSX icon
3
Biodesix
BDSX
$209M
$9.08M 6.18%
55,248
– –
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$8.42M 5.73%
59,684
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$7.69M 5.23%
80,200
– –
FHTX icon
6
Foghorn Therapeutics
FHTX
$305M
$4.38M 2.98%
314,143
– –
BIIB icon
7
Biogen
BIIB
$30.4B
$3.57M 2.43%
12,600
+500
+4% +$164K
ALBO
8
DELISTED
Albireo Pharma Inc
ALBO
$3.53M 2.4%
113,000
+2,000
+2% +$61.9K
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.32M 2.26%
18,000
– –
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$4.38B
$3.31M 2.25%
199,400
– –
PRTA icon
11
Prothena Corp
PRTA
$453M
$2.87M 1.95%
40,247
+10,000
+33% +$621K
MASI
12
DELISTED
Masimo
MASI
$2.17M 1.47%
8,000
– –
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$1.84M 1.25%
10,672
-8,000
-43% -$1.05M
CLR
14
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.78M 1.21%
38,600
– –
HROW icon
15
Harrow
HROW
$1.74B
$1.64M 1.11%
180,000
– –
BLUE
16
DELISTED
bluebird bio
BLUE
$1.6M 1.09%
6,485
+772
+14% +$221K
ALKS icon
17
Alkermes
ALKS
$8.79B
$1.54M 1.05%
50,000
– –
AMRN
18
Amarin Corp
AMRN
$292M
$1.53M 1.04%
15,000
– –
KPTI icon
19
Karyopharm Therapeutics
KPTI
$216M
$1.43M 0.97%
16,400
+1,067
+7% +$111K
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.39M 0.95%
10,000
– –
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$327M
$1.37M 0.93%
80,000
– –
ETRN
22
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.35M 0.92%
133,050
– –
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.31M 0.89%
22,000
– –
NKTR icon
24
Nektar Therapeutics
NKTR
$2.31B
$1.29M 0.88%
4,800
– –
ARVN icon
25
Arvinas
ARVN
$517M
$1.23M 0.84%
15,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Birchview Capital held 67 positions worth $147M, down 12% from $167M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q3 2021 filing shows 5 new, 11 increased, 3 reduced and 3 closed positions. Its largest new stake was Gossamer Bio: 40,000 shares worth $503K. The largest sale was Acceleron Pharma, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2021 buy was Gossamer Bio: 40,000 shares worth $503K.
  • Birchview Capital added most to Protagonist Therapeutics in Q3 2021, an estimated $1.19M increase.
  • Birchview Capital's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $1.05M.
  • Birchview Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $826K.
  • Birchview Capital's ten largest holdings make up 70% of its $147M portfolio in Q3 2021.
  • Birchview Capital opened 5 new positions and closed 3 in Q3 2021.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $147M.

Based on Birchview Capital's 13F filing for Q3 2021, filed 12 Nov 2021.